期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (2)
Purpose. Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was ......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (4)
We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (5)
The discovery and development of effective novel compounds is paramount in oncology for improving cancer therapy. In this study, we developed a new de......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (1)
The survival benefit of icotinib (an oral epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced lung cancer has......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (1)
Lysine-specific demethylase 1 (LSD1) has been a promising target to treat prostate cancer, and discovery of novel LSD1 inhibitors would have great cli......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (2)
Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies. However, CAR-T cell therapy......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (3)
Talazoparib, a poly(ADP-ribose) polymerase inhibitor, has demonstrated efficacy in the treatment of advanced breast and prostate cancers in Western po......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (4)
Precise selection of patients who could benefit from immune checkpoint inhibitors (ICIs) is an important challenge for immunotherapy in lung cancer. P......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (1)
To determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid t......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (1)
Background Neoadjuvant and adjuvant immune checkpoint inhibitor treatments for non-small cell lung cancer (NSCLC) patients with resectable disease hav......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (2)
Background: To investigate the clinical features of nivolumab-induced myasthenia gravis (MG) and provide evidence for the rational use of nivolumab in......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (3)
Immune-related sclerosing cholangitis (irSC) is relatively rare and its clinical characteristics are not well known. In this study, we aimed to summar......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (5)
Recombinant human arginase I (rhArg I) have emerged as a potential candidate for the treatment of varied pathophysiological conditions ranging from ar......
期刊： INVESTIGATIONAL NEW DRUGS, 2023; 41 (2)
The usage of monoclonal antibodies (mAbs) and antibody fragments, as a matter associated with the biopharmaceutical industry, is increasingly growing.......
